


Liver Capsule:

FXR AGONISTS AGAINST LIVER DISEASE

Claudia D. Fuchs, * Philipp Schwabi, * Thomas Reiberger, and Michael Trauner

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
*These authors contributed equally to this work. Corresponding author: michael.trauner@meduniwien.ac.at

HEPATOLOGY



Received July 12, 2016; accepted August 3, 2016. DOI 10.1002/hep.28836
Copyright © 2016 The Authors. *Hepatology* published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. This work was supported by grants F3008 and F3517 from the Austrian Science Foundation (to MT).

Potential conflict of interest: Dr. Trauner consults, is on the speakers' bureau, and received grants from Falk and Gilead. He consults and is on the speakers' bureau for MSD. He consults and received grants from Intercept and Albeiro. He is on the speakers' bureau and received grants from Roche. He consults for Phenex and Novartis. Dr. Reiberger consults for Xult and received grants from Phenex. He received grants and speaker honoraria from Roche, Gilead, and MSD.

References

- Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet* 2015;395:956-965.
- Bagdasaryan A, Claudel T, Gunnild J, Silber D, Adorini L, Rode A, et al. Dual farnesoid X receptor/THR5 agonist INT-767 reduces liver injury in the Mdr2^{-/-} (Abcb4^{-/-}) mouse cholangiopathy model by promoting biliary HCO₃⁻ output. *Hepatology* 2011;54:1303-1312.
- Inagaki T, Moschiana A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci USA* 2006;7:103:3920-3925.
- Nevens F, Andreone P, Mazzella G, Strasser S, Bowmus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. *N Engl J Med* 2016;375:631-643.

5. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. *Hepatology* 2014;59:2286-2298.

Abbreviations: ASBT, apical sodium-dependent bile acid transporter; BA, bile acid; BSEP, bile salt export pump; CA, cancer antigen; CDCA, chenodeoxycholic acid; Chol, cholesterol; Col1α, collagen 1α; COX2, cyclooxygenase 2; eNOS, endothelial NO synthase; ET1, endothelin 1; FA, fatty acid; FFA, free fatty acid; FGF, fibroblast growth factor; FGFR, FGF receptor; FXR, farnesoid X receptor; HCC, hepatocellular carcinoma; HDL, high-density lipoprotein; IFN, interferon; IGF1R, insulin-like growth factor 1 receptor; IL, interleukin; INOS, inducible NO synthase; KC, Kupfer cell; LDL, low-density lipoprotein; LDLr, LDL receptor; Lp(a), lipoprotein a; LSEC, liver sinusoidal endothelial cell; MCP1, monocyte chemoattractant protein 1; MDR, multidrug resistance; MMP, matrix metalloproteinase; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NF-κB, nuclear factor kappa B; NO, nitric oxide; NTCP, sodium/nitrocholate cotransporting polypeptide; PL, phospholipid; SR-B1, scavenger receptor class B type 1; p-STAT3, phosphorylated signal transducer and activator of transcription 3; TG, triglyceride; TGF-β, transforming growth factor; TIMP, tissue inhibitor of metalloproteinase; TJ, tight junction; TNF-α, tumor necrosis factor; VCAM, vascular cell adhesion molecule; VLDL, very low-density lipoprotein; ZO-1, zona occludens 1.